目的 探讨七蕊胃舒胶囊联合兰索拉唑肠溶胶囊治疗慢性浅表性胃炎的临床疗效。方法 选取2023年6月—2024年6月在上海交通大学医学院附属第六人民医院确诊并规范治疗的100例慢性浅表性胃炎患者作为研究对象，按照确诊入组的时间顺序将其分为对照组和治疗组，每组各有50例。对照组患者采用兰索拉唑肠溶胶囊口服治疗，1次30 mg，1日1次。治疗组患者在对照组治疗基础上加用七蕊胃舒胶囊口服治疗，1次4粒，1日2次，于早晚饭前0.5 h服用。两组患者均接受了为期4周的连续治疗。观察两组患者的临床疗效，比较两组治疗前后中医证候评分、慢性病患者生命质量测定量表（QLICD-CG）评分、血清胃泌素（GAS）、胃蛋白酶原Ⅰ（PGI）及胃泌素17（G-17）水平的变化情况。结果 规律治疗后，治疗组和对照组总有效率分别为96.00%、84.00%，组间比较有显著性差异（P＜0.05）。治疗后，两组患者中医证候评分均较治疗前显著下降，而QLICD-CG评分均较治疗前显著升高（P＜0.05）；相关评分方面治疗组患者明显优于对照组（P＜0.05）。治疗后，两组患者血清GAS、G-17水平均显著降低，而PGI水平则显著提升（P＜0.05）；治疗后，治疗组患者GAS、G-17水平低于对照组，PGI水平高于对照组（P＜0.05）。结论 七蕊胃舒胶囊联合兰索拉唑治疗慢性浅表性胃炎疗效显著，可有效减轻患者临床症状，提升生活质量，同时促进血清学相关指标的恢复，具备广泛的临床应用前景。

Objective To investigate the therapeutic effect of Qirui Weishu Capsules combined with lansoprazole in treatment of chronic superficial gastritis. Methods A total of 100 patients with chronic superficial gastritis diagnosed and treated in the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2023 to June 2024 were selected as the study objects, and were divided into control group and treatment group according to the chronological order of diagnosis and inclusion, with 50 cases in each group. Patients in control group were po administered with Lansoprazole Enteric Capsules, 30 mg/time, once daily. Patients in treatment group were po administered with Qirui Weishu Capsules on basis of control group, 4 capsules/time, twice daily, half an hour before morning and evening meals. Both groups received continuous treatment for 4 weeks. The clinical efficacy of the two groups was observed, and the changes of TCM syndrome score, QLICD-CG score, GAS, PGI, and G-17 levels before and after treatment were compared between two groups. Results After regular treatment, the total effective rate of treatment group and control group was 96.00% and 84.00%, respectively, with significant difference between groups (P < 0.05). After treatment, TCM syndrome scores in both groups were significantly decreased, but QLICD-CG scores were significantly increased compared with before treatment (P < 0.05). The scores in treatment group were significantly better than those in control group (P < 0.05). After treatment, serum GAS and G-17 levels were significantly decreased, but PGI levels were significantly increased in two groups (P < 0.05). After treatment, GAS and G-17 levels in treatment group were lower than those in control group, but PGI levels were higher than those in control group (P < 0.05). Conclusion Qirui Weishu Capsules combined with lansoprazole is effective in treatment of chronic superficial gastritis, and can effectively reduce the clinical symptoms of patients, improve the life quality, and promote the recovery of serological related indicators, which has a wide range of clinical application prospects.

R975

国家自然科学基金资助项目（82074063）